Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Abstract

Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.

• Authors: Paolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, Michele Del Vecchio, Paolo Marchetti, Gian Carlo Antonini Cappellini, Ruggero Ridolfi, Francesco de Rosa, Francesco Cognetti, Virginia Ferraresi, Alessandro Testori, Paola Queirolo, Maria Grazia Bernengo, Michele Guida, Luca Galli, Mario Mandalà, Carolina Cimminiello, Gaetana Rinaldi, Fabrizio Carnevale-Schianca, Michele Maio
• Journal: Cancer investigation (Cancer Invest) Vol. 32 Issue 4 Pg. 144-9 (May 2014) ISSN: 1532-4192 [Electronic] England
• PMID: 24484235 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Imidazoles
• Indoles
• Ipilimumab
• Oximes
• Protein Kinase Inhibitors
• Sulfonamides
• Vemurafenib
• BRAF protein, human
• Proto-Oncogene Proteins B-raf
• dabrafenib

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Disease Progression
• Drug Administration Schedule
• Female
• Humans
• Imidazoles (administration & dosage)
• Indoles (administration & dosage)
• Ipilimumab
• Italy
• Kaplan-Meier Estimate
• Male
• Melanoma (drug therapy, enzymology, genetics, mortality, secondary)
• Middle Aged
• Molecular Targeted Therapy
• Mutation
• Oximes (administration & dosage)
• Protein Kinase Inhibitors (administration & dosage)
• Proto-Oncogene Proteins B-raf (antagonists & inhibitors, genetics, metabolism)
• Retrospective Studies
• Skin Neoplasms (drug therapy, enzymology, genetics, mortality, pathology)
• Sulfonamides (administration & dosage)
• Time Factors
• Treatment Outcome
• Vemurafenib
• Young Adult